查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1454244

全球抗生素抗藥性市場：按藥物類別、疾病、分銷管道和地區分類

Global Antibiotic Resistance Market, By Drug Class, By Disease (cUTI, CDI, ABSSSI, HABP, CABP, cIAI, Others (BSI, etc.)), By Distribution Channel, By Geography .
出版日期: | 出版商: Coherent Market Insights | 英文 180 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2023年全球抗生素抗藥性市場價值為88.3億美元，預計2031年將達133.7億美元，2024年至2031年年複合成長率為5.3%。

報告範圍 報告詳情
基準年 2023年 2023/2024年市場規模 88.3億美元
實際資料 2019-2023 預測期 2024-2031
預測期間2023/2024 至2030/2031年年複合成長率： 5.30% 2030/2031價值預測 133.7億美元
圖 1.2023年全球抗生素抗藥性市場佔有率（%）（依地區）
全球抗生素抗藥性市場-IMG1

近年來，全球抗生素抗藥性市場經歷了顯著成長。抗生素是用於預防和治療細菌感染的藥物。抗生素會殺死細菌或阻止其生長。最常使用的抗生素包括青黴素、阿莫西林和頭孢菌素。然而，在過去的幾十年裡，抗生素抗藥性已成為全球公共衛生的主要威脅。當細菌對抗生素產生抗藥性時，用於治療細菌引起的感染疾病的藥物就會失效。結果，疾病時間延長，死亡率增加。對各種抗生素具有抗藥性的細菌菌株數量不斷增加，主要是由於抗生素的濫用和過度使用。促進抗生素抗藥性的其他因素包括缺乏新抗生素的開發、世界許多地區缺乏衛生設施以及國際旅行的增加。如果處理不當，抗生素抗藥性可能會導致嚴重的健康問題並影響患者的治療結果。

市場動態：

全球抗生素抗藥性市場的成長是由抗生素抗藥性細菌感染疾病日益流行、新抗生素缺乏市場開拓、現有抗生素濫用和過度使用以及許多新興市場的感染控制有限所推動的。等因素。然而，替代治療方法的發展和有關抗生素使用的嚴格規定可能會抑制市場成長。該市場為致力於開拓具有新作用機制的新型抗生素的公司提供了機會。主要企業也在探索替代治療方法，例如噬菌體療法、疫苗和單株抗體，以對抗抗生素抗藥性。工業界和學術界之間的合作是解決這一迫在眉睫的醫療保健危機的一個有希望的途徑。

本研究的主要特點

  • 本報告詳細分析了全球抗生素抗藥性市場，並提供了以2023年為基準年的預測期（2024-2031）的市場規模和年複合成長率（CAGR%）。
  • 說明了各個細分市場的潛在收益成長機會，並為該市場提供了一系列有吸引力的投資提案。
  • 提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要見解。
  • 根據公司亮點、產品系列、主要亮點、財務表現和策略等參數，介紹了全球抗生素抗藥性市場的主要企業。
  • 本報告的見解使負責人和公司經營團隊能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
  • 全球抗生素抗藥性市場報告迎合了該行業的各個相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
  • 相關人員可以透過用於分析全球抗生素抗藥性市場的各種策略矩陣來促進他們的決策。

目錄

第1章 研究目的與前提

  • 研究目標
  • 先決條件
  • 簡稱

第2章 市場展望

  • 報告說明
    • 市場定義和範圍
  • 執行摘要
  • Coherent Opportunity Map（COM）

第3章 市場動態、法規及趨勢分析

  • 市場動態
    • 感染疾病的傳播
    • 抗生素抗藥性診斷的進展
    • 增加研發活動
  • 主要亮點
  • 臨時勞務派遣機構和公司指南
  • 市場趨勢
  • PEST分析
  • 投資金籌措
  • 合併、收購和合作
  • 主要提供服務
  • 識別頂級市場參與者
  • 護士安置的優勢
  • 依國家分類的醫療保健支出

第4章 全球抗生素抗藥性市場－冠狀病毒（COVID-19）大流行的影響

  • 新型冠狀病毒感染疾病（COVID-19）的流行病學
  • 供需面分析
  • 經濟影響

第5章 全球抗生素抗藥性市場，依藥物類別，2019-2031

  • Oxazolidinone
  • 胜肽
  • 四環黴素
  • 頭孢菌素類
  • 其他（聯合治療等）

第6章 全球抗生素抗藥性市場，依疾病分類，2019-2031

  • cUTI（複雜性尿道感染）
  • CDI（困難梭狀桿菌感染疾病）
  • ABSSSI（急性細菌性皮膚和皮膚結構感染疾病）
  • HABP（醫院細菌性肺炎）
  • CABP（社區型肺炎）
  • cIAI（複雜性腹腔內感染疾病）
  • 其他（BSI（血流感染疾病）等）

第7章 全球抗生素抗藥性市場，依通路，2019-2031

  • 醫院藥房
  • 零售藥房
  • 網路藥房

第8章 全球抗生素抗藥性市場，依地區，2019-2031

  • 北美洲
  • 美國
  • 加拿大
  • 歐洲
  • 德國
  • 英國
  • 西班牙
  • 法國
  • 義大利
  • 俄羅斯
  • 歐洲其他地區
  • 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • ASEAN
  • 其他亞太地區
  • 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲
  • 中東
  • 海灣合作理事會國家
  • 以色列
  • 其他中東地區
  • 非洲
  • 北非
  • 中部非洲
  • 南非

第9章 競爭格局

  • 公司簡介
    • Melinta Therapeutics
    • Merck &Co., Inc.
    • Allergan
    • Pfizer Inc.
    • Tetraphase Pharmaceutical, Inc.
    • TeamHealth
    • Theravance Biopharma
    • WOCKHARDT
    • Entasis Threapeutics
    • Paratek Pharmaceutials, Inc.
    • Seres Therapeutics
    • Achaogen Inc.
    • Basilea Pharmaceutical Ltd.
    • Nabriva Threapeutics plc
    • NEMESIS BIOSCIENCE LTD.

第10章

  • 參考
  • 調查方法
  • 關於出版商
簡介目錄
Product Code: CMI6668

The global antibiotic resistance market was valued US$ 8.83 Bn in 2023 and is expected to reach US$ 13.37 Bn by 2031, growing at a compound annual growth rate (CAGR) of 5.3% from 2024 to 2031.

Report Coverage Report Details
Base Year: 2023 Market Size in 2023/2024: US$ 8.83 Bn
Historical Data for: 2019 to 2023 Forecast Period: 2024 - 2031
Forecast Period 2023/2024 to 2030/2031 CAGR: 5.30% 2030/2031 Value Projection: US$ 13.37 Bn
Figure 1. Global Antibiotic Resistance Market Share (%), By Region, 2023
Global Antibiotic Resistance Market - IMG1

The global antibiotic resistance market has been witnessing significant growth in recent years. Antibiotics are medicines used to prevent and treat bacterial infections. They either kill bacteria or stop them from multiplying. Some of the most commonly used antibiotics include penicillin, amoxicillin, cephalosporins etc. However, over the past few decades, antibiotic resistance has been emerging as a major public health threat globally. When bacteria become antibiotic resistant, the medicines used to treat the infections they cause become ineffective. This leads to longer illness and increased death rates. The rising prevalence of bacterial strains that are resistant to various antibiotic classes is primarily attributable to misuse and overuse of antibiotics. Other factors that drive antibiotic resistance include the lack of development of new antibiotics, lack of sanitation and hygiene in many parts of the world, increased international travels, etc. If not addressed properly, antibiotic resistance could lead to serious health issues and affect patient outcomes.

Market Dynamics:

The global antibiotic resistance market growth is driven by various factors such as increasing prevalence of antibiotic-resistant bacterial infections, lack of new antibiotic development, misuse and overuse of existing antibiotics, limited infection control in many developing regions, etc. However, the development of alternative treatment options and stringent regulations regarding antibiotic usage could restrain the market growth. The market provides opportunities for companies focusing on the development of novel antibiotics with new mechanisms of action. Key players are also exploring alternative therapeutic approaches like phage therapy, vaccines, monoclonal antibodies etc. to counter antibiotic resistance. Partnerships between industry and academia hold promise to address this looming healthcare crisis.

Key Features of the Study:

  • This report provides an in-depth analysis of the global antibiotic resistance market, and provides market size (US$ Bn) and compound annual growth rate (CAGR %) for the forecast period (2024-2031), considering 2023 as the base year
  • It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global antibiotic resistance market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Melinta Therapeutics, Merck & Co., Inc., Allergan, Pfizer Inc., Tetraphase Pharmaceutical, Inc., Theravance Biopharma, WOCKHARDT, Entasis Threapeutics, Paratek Pharmaceutials, Inc., Seres Therapeutics, Achaogen Inc., Basilea Pharmaceutical Ltd., Nabriva Threapeutics plc, NEMESIS BIOSCIENCE LTD.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global antibiotic resistance market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antibiotic resistance market

Detailed Segmentation:

  • Global Antibiotic Resistance Market, By Drug Class
    • Oxazolidinones
    • Lipoglycopeptides
    • Tetracyclines
    • Cephalosporins
    • Others (Combination therapies, etc.)
  • Global Antibiotic Resistance Market, By Disease
    • cUTI (Complicated Urinary Tract Infections)
    • CDI (Clostridioides difficile Infection)
    • ABSSSI (Acute bacterial skin and skin structure infections)
    • HABP (Hospital-acquired bacterial pneumonia)
    • CABP (Community-acquired pneumonia)
    • cIAI (Complicated intra-abdominal infection)
    • Others (BSI (Bloodstream infection), etc.)
  • Global Antibiotic Resistance Market, By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Antibiotic Resistance Market, By Region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Top Companies in the Global Antibiotic Resistance Market:
    • Melinta Therapeutics
    • Merck & Co., Inc.
    • Allergan
    • Pfizer Inc.
    • Tetraphase Pharmaceutical, Inc.
    • Theravance Biopharma
    • WOCKHARDT
    • Entasis Threapeutics
    • Paratek Pharmaceutials, Inc.
    • Seres Therapeutics
    • Achaogen Inc.
    • Basilea Pharmaceutical Ltd.
    • Nabriva Threapeutics plc
    • NEMESIS BIOSCIENCE LTD.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Class
    • Market Snippet, By Disease
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Rising prevalence of infectious diseases
    • Advancement in antibiotic resistance diagnosis
    • Growing number of R&D activities
  • Key Highlights
  • Guidelines for the Temporary Staffing Agency & the Host Employer
  • Market Trends
  • PEST Analysis
  • Investments and Fundings
  • Mergers, Acquisitions, and Collaborations
  • Key Services Offered
  • Identification of Top Market Players
  • Nurse Staffing Dominance
  • Healthcare Spending by Country

4. Global Antibiotic Resistance Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Antibiotic Resistance Market, By Drug Class, 2019-2031, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Oxazolidinones
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • Lipoglycopeptides
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • Tetracyclines
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • Cephalosporins
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • Others (Combination therapies, etc.)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)

6. Global Antibiotic Resistance Market, By Disease, 2019-2031, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • cUTI (Complicated Urinary Tract Infections)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • CDI (Clostridioides difficile Infection)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • ABSSSI (Acute bacterial skin and skin structure infections)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • HABP (Hospital-acquired bacterial pneumonia)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • CABP (Community-acquired pneumonia)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • cIAI (Complicated intra-abdominal infection)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • Others (BSI (Bloodstream infection), etc.)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)

7. Global Antibiotic Resistance Market, By Distribution Channel, 2019-2031, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)

8. Global Antibiotic Resistance Market, By Region, 2019-2031, (US$ Bn)

  • Introduction
    • Market Share Analysis, By Region, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, For Region, 2020 - 2031
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Disease, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031, (US$ Bn)
  • U.S.
  • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Disease, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031, (US$ Bn)
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Disease, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031, (US$ Bn)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Disease, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031, (US$ Bn)
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Disease, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031, (US$ Bn)
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Disease, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019-2031, (US$ Bn)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

  • Company Profile
    • Melinta Therapeutics
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
    • Merck & Co., Inc.
    • Allergan
    • Pfizer Inc.
    • Tetraphase Pharmaceutical, Inc.
    • TeamHealth
    • Theravance Biopharma
    • WOCKHARDT
    • Entasis Threapeutics
    • Paratek Pharmaceutials, Inc.
    • Seres Therapeutics
    • Achaogen Inc.
    • Basilea Pharmaceutical Ltd.
    • Nabriva Threapeutics plc
    • NEMESIS BIOSCIENCE LTD.
  • Analyst Views

10. Section

  • References
  • Research Methodology
  • About us